MREO Overview
Upcoming Projects (MREO)
-
Don’t see a project related to the company you care about? Create your own!
Executed Projects (MREO)
-
A Second Look at setrusumab (UX143) for the treatment of osteogenesis imperfecta ahead of the Phase 3 randomized, placebo-controlled readout
Tickers: RARE, MREO
Executed On: Dec 12, 2025 at 10:30 AM EST -
A look at Ultragenyx setrusumab (UX143) for the treatment of osteogenesis imperfecta ahead of the Phase 3 clinical trial readout
Tickers: RARE, MREO
Executed On: Dec 08, 2025 at 02:00 PM EST -
Discussing the Phase 2/3 Orbit Study of Ultragenyx' Setrusumab (UX143) in treating Osteogenesis Imperfecta
Tickers: RARE, MREO
Executed On: Jun 30, 2023 at 02:00 PM EDT
Expired Projects (MREO)
-
Discussing Mereo BioPharma MPH-966 (Alvelestat) in treating Severe AATD (alpha-1 antitrypsin deficiency)
Ticker: MREO
Execute By: Jun 30, 2023
Upcoming & Overdue Catalysts (MREO)
-
Don’t see a catalyst related to the company you care about? Create your own!
Strategic Initiatives (MREO)
-
Don’t see a strategic initiative related to the company you care about? Create your own!
